July 16, 2013
Mylan Pharmaceuticals Inc. and Sandoz Inc. on Tuesday escaped almost identical infringement suits by Teva Pharmaceuticals Ltd. after they agreed to stop using its patented technology in seeking U.S. Food and Drug Administration approval for generic versions of Teva's multiple sclerosis drug Copaxone.
May 13, 2013
Teva Pharmaceuticals Ltd. on Monday defended its patent suit over rival Sandoz Inc.'s attempt to develop a generic version of its multiple sclerosis drug Copaxone, saying legal safe harbors that protect generic development do not apply in this case.
April 18, 2013
Sandoz Inc. asked a New York federal judge Wednesday to toss Teva Pharmaceuticals Industries Ltd.'s patent infringement suit, saying its use of a patented process as it developed a generic form of multiple sclerosis drug Copaxone was protected by the safe harbor exemption.